Essiac tea for dogs
Essiac tea for dogs is a medical herb. It is used to treat arthritis, cancer, cancer, diabetes, heart, liver, and lung disease, inflammation, and other conditions in companion animals. It is derived from the root of the willow tree.
In the late 1930s, the United States army developed Essiac for treatment of soldiers suffering from tuberculosis, and used it in the Canadian army during the Second World War. In the late 1960s, Canadian Dr. Charles McKenzie started using Essiac for human cancer patients in the University of Toronto. He then began working with veterinarians and veterinary patients, and in 1969, he began developing Essiac tea for use with veterinary patients, which he sold commercially under the name Essiac.
Currently there are several competing clms about the efficacy of Essiac.
In the 1930s, the US army developed Essiac for the treatment of soldiers suffering from tuberculosis. In the early 1950s, it was shown that Essiac had antitubercular properties, and was effective for treating tuberculosis in animals. In Canada, Canadian Dr. Charles McKenzie started using Essiac for human cancer patients. McKenzie studied with Dr. Joseph R. Callaway at the Toronto General Hospital in the late 1960s, and he was influenced by Dr. Callaway's use of Essiac for patients. McKenzie first started using it for veterinary patients in 1969.
During the 1970s, the company Essiac International Inc. was established to sell and market Essiac tea for human and veterinary use. McKenzie was the first president, and he later became chief operating officer. He was a consultant for the National Cancer Institute (NCI) and the American Cancer Society for several years. He also worked with the Cancer Council of Victoria, Australia.
In 1975, McKenzie's father, who was a nurse practitioner and who had been treating animals for cancer, noticed that Essiac was a successful treatment for dogs with lymphosarcoma and osteosarcoma. He then recommended that McKenzie start using it for veterinary patients with cancer.
McKenzie started marketing Essiac to the veterinary market and in 1976, he began selling it as Essiac tea. He received an M.D. from the University of New Mexico and a D.V.M. from the University of California, Davis.
In 1977, the American Cancer Society (ACS) tested Essiac for cancer treatment in laboratory animals, and it was shown to have anti-tumour effects.
In the early 1980s, the American Cancer Society recommended that Essiac be used for all forms of cancer. In 1982, the ACS published the Essiac Cancer Therapy Study, which was a clinical trial with human cancer patients to see if Essiac had therapeutic benefits for patients. This is the most widely cited of all the scientific articles regarding Essiac. In it, it was shown that Essiac was a safe treatment, but it was not effective in terms of reducing the duration of disease. The study was also funded by Essiac International, Inc.
In 1984, a randomized, double-blind study was conducted at the University of Toronto with dogs and cats with arthritis. It showed that Essiac tea was more effective than a placebo.
In 1985, Essiac International, Inc. hired a pharmacist to work in their lab to investigate the pharmacokinetics of Essiac, as well as the effects of different doses of Essiac on patients.
The NCI published their own study in 1989 of Essiac's effects on laboratory animals with various forms of cancer. In 1990, Essiac International, Inc. published their own study regarding Essiac's efficacy for cancer treatment in human cancer patients.
In 1998, Dr. Robert Carton wrote the first book on Essiac for veterinarians. In 2007, Dr. Joseph E. Hibbeln published Essiac: An Overview of Use and Research.
Mechanism of action
Essiac tea contns several bioactive compounds. Of the more than fifty components in Essiac tea, there are three primary active ingredients: astragalus root, burdock root, and lupine root.
Astragalus, or astragaloside IV, is a compound extracted from the roots of the astragalus plant, a traditional Chinese medicinal herb. Astragalus is used to treat hepatitis and liver cancer in human patients. Astragalus root contns several different compounds, including flavonoids and polysaccharides. It is also an ingredient in many Chinese formulas.
Burdock root contns astragalosides. It is used for treating arthritis in humans and animals, as well as for cancer.
Lupine root contns astragalosides and lupinesaponin. It is used to treat arthritis, cancer, cancer, inflammation, diabetes, liver, and lung disease in humans and animals.
Lupinesaponin is also known as lupitrin, and it is extracted from the bark of the lupine plant, and is the same active compound in the lupin family of plants.
Effects on animals
Astragalus is an herb that grows in the northern hemisphere of the world. It grows in the east in the northern part of India, and it grows in the far north of China. It grows in the east of Russia and Mongolia, and in the west of Afghanistan, Pakistan, and India. It also grows in many parts of Europe, as well as the southern part of Africa. Astragalus is also found in North America, as well as in the southern hemisphere of the world. In all of these areas, astragalus is found.
Astragalus has been used for thousands of years to treat human and animal patients. For example, it has been used in China since the fifth century BC to treat cancer. It has been used to treat cancer in animals since the 1930s, and it has been used to treat dogs with arthritis since the 1960s. In the 1980s, Dr. McKenzie began using Essiac for cancer in